Perspectives Risk categories and refractory CLL in the era of chemoimmunotherapy

1Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany; 2Department of Medicine V, University of Heidelberg, Heidelberg, Germany; 3Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; 4Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, and Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases, University of Cologne, Cologne, Germany; 5Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; and 6Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX